APA (7th ed.) Citation

Kumar, R., Agarwal, P., Anderson, K., Claassen, D., Dean, M., Duker, A., . . . Kroon, H. (2026). An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease. Movement Disorders, 41(6), 1492. https://doi.org/10.1002/mds.70229

Chicago Style (17th ed.) Citation

Kumar, Rajeev, et al. "An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease." Movement Disorders 41, no. 6 (2026): 1492. https://doi.org/10.1002/mds.70229.

MLA (9th ed.) Citation

Kumar, Rajeev, et al. "An Open‐Label Phase 1b Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ANX005 in Patients with Huntington's Disease." Movement Disorders, vol. 41, no. 6, 2026, p. 1492, https://doi.org/10.1002/mds.70229.